Qi Cao, Xiao Wu, Juan Tan, Hanying Xu, Ying Zhang, Yang Hu, Yuxi Chen, Shiyong Zhang and Tian Tang*,
{"title":"Targeting GPX4-Dependent Ferroptosis via a Dihydroartemisinin-Conjugated Cross-Linked Lipoic Acid Nanodrug for Endometrial Carcinoma Therapy","authors":"Qi Cao, Xiao Wu, Juan Tan, Hanying Xu, Ying Zhang, Yang Hu, Yuxi Chen, Shiyong Zhang and Tian Tang*, ","doi":"10.1021/acs.bioconjchem.5c00256","DOIUrl":null,"url":null,"abstract":"<p >Endometrial cancer (EC) is a significant global cause of cancer-related mortality. Chemoresistance is a major challenge in treating advanced or recurrent EC, necessitating the search for new anti-EC drugs. Dihydroartemisinin (DHA)-induced ferroptosis shows promise as a therapy for EC, but its poor solubility and insufficient antitumor potency hinder its clinical use. A novel nanodrug delivery system, DHA@cLAVs, was developed using cross-linked lipoic acid to enhance DHA solubility and antitumor efficacy. Benefiting from the pro-oxidant effects of lipoic acid on tumor cells and its improved water solubility, DHA@cLAVs outperformed DHA alone, showing promising ferroptosis-based antitumor effects via the c-jun/c-fos-GPX4 pathway in both in vitro and in vivo experiments, offering promising prospects for endometrial carcinoma treatment.</p>","PeriodicalId":29,"journal":{"name":"Bioconjugate Chemistry","volume":"36 7","pages":"1541–1552"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioconjugate Chemistry","FirstCategoryId":"1","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.bioconjchem.5c00256","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Endometrial cancer (EC) is a significant global cause of cancer-related mortality. Chemoresistance is a major challenge in treating advanced or recurrent EC, necessitating the search for new anti-EC drugs. Dihydroartemisinin (DHA)-induced ferroptosis shows promise as a therapy for EC, but its poor solubility and insufficient antitumor potency hinder its clinical use. A novel nanodrug delivery system, DHA@cLAVs, was developed using cross-linked lipoic acid to enhance DHA solubility and antitumor efficacy. Benefiting from the pro-oxidant effects of lipoic acid on tumor cells and its improved water solubility, DHA@cLAVs outperformed DHA alone, showing promising ferroptosis-based antitumor effects via the c-jun/c-fos-GPX4 pathway in both in vitro and in vivo experiments, offering promising prospects for endometrial carcinoma treatment.
期刊介绍：
Bioconjugate Chemistry invites original contributions on all research at the interface between man-made and biological materials. The mission of the journal is to communicate to advances in fields including therapeutic delivery, imaging, bionanotechnology, and synthetic biology. Bioconjugate Chemistry is intended to provide a forum for presentation of research relevant to all aspects of bioconjugates, including the preparation, properties and applications of biomolecular conjugates.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
